How we manage patients with heparin induced thrombocytopenia

British Journal of Haematology

Volumn 174, Issue 1, 2016, Pages 9-15

  Scully, Marie ^a   Gates, Carolyn ^a   Neave, Lucy ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

direct acting oral anticoagulants; heparin induced thrombocytopenia; non heparin anticoagulants; thrombosis

Indexed keywords

ARGATROBAN; DANAPAROID; FC RECEPTOR IIA; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBOCYTE FACTOR 4; WARFARIN;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CROSS REACTION; DIAGNOSTIC ACCURACY; DISEASE DURATION; DISEASE SEVERITY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LYMPHOCYTE ACTIVATION; MORTALITY RATE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION ANALYZER;

EID: 84976465912     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14102     Document Type: Review

References (54)

1. Alatri, A., Armstrong, A.E., Greinacher, A., Koster, A., Kozek-Langenecker, S.A., Lance, M.D., Link, A., Nielsen, J.D., Sandset, P.M., Spanjersberg, A.J. & Spannagl, M. (2012) Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. Thrombosis Research, 129, 426–433.
2. Bartholomew, J.R. & Hursting, M.J. (2005) Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated International Normalized Ratio (INR). Journal of Thrombosis and Thrombolysis, 19, 183–188.
3. Beiderlinden, M., Treschan, T., Gorlinger, K. & Peters, J. (2007a) Argatroban in extracorporeal membrane oxygenation. Artificial Organs, 31, 461–465.
4. Beiderlinden, M., Treschan, T.A., Gorlinger, K. & Peters, J. (2007b) Argatroban anticoagulation in critically ill patients. Annals of Pharmacotherapy, 41, 749–754.
5. Cook, D., Crowther, M., Meade, M., Rabbat, C., Griffith, L., Schiff, D., Geerts, W. & Guyatt, G. (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Critical Care Medicine, 33, 1565–1571.
6. Cook, D., Meade, M., Guyatt, G., Walter, S., Heels-Ansdell, D., Warkentin, T.E., Zytaruk, N., Crowther, M., Geerts, W., Cooper, D.J., Vallance, S., Qushmaq, I., Rocha, M., Berwanger, O. & Vlahakis, N.E. (2011) Dalteparin versus unfractionated heparin in critically ill patients. New England Journal of Medicine, 364, 1305–1314.
7. Crowther, M., Cook, D., Guyatt, G., Zytaruk, N., McDonald, E., Williamson, D., Albert, M., Dodek, P., Finfer, S., Vallance, S., Heels-Ansdell, D., McIntyre, L., Mehta, S., Lamontagne, F., Muscedere, J., Jacka, M., Lesur, O., Kutsiogiannis, J., Friedrich, J., Klinger, J.R., Qushmaq, I., Burry, L., Khwaja, K., Sheppard, J.A. & Warkentin, T.E. (2014) Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. Journal of Critical Care, 29, 470.e477-415
8. Cuker, A., Arepally, G., Crowther, M.A., Rice, L., Datko, F., Hook, K., Propert, K.J., Kuter, D.J., Ortel, T.L., Konkle, B.A. & Cines, D.B. (2010) The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. Journal of Thrombosis and Haemostasis, 8, 2642–2650.
9. Goel, R., Ness, P.M., Takemoto, C.M., Krishnamurti, L., King, K.E. & Tobian, A.A. (2015) Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood, 125, 1470–1476.
10. Gray, A., Wallis, D.E., Hursting, M.J., Katz, E. & Lewis, B.E. (2007) Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clinical and Applied Thrombosis/Hemostasis, 13, 353–361.
11. Greinacher, A. (2015) CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 373, 252–261.
12. Greinacher, A., Farner, B., Kroll, H., Kohlmann, T., Warkentin, T.E. & Eichler, P. (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thrombosis and Haemostasis, 94, 132–135.
13. Hantson, P., Lambert, C. & Hermans, C. (2015) Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 26, 205–206.
14. Joseph, L., Casanegra, A.I., Dhariwal, M., Smith, M.A., Raju, M.G., Militello, M.A., Gomes, M.P., Gornik, H.L. & Bartholomew, J.R. (2014) Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 12, 1044–1053.
15. Joseph, L., Gomes, M.P., Al Solaiman, F., St John, J., Ozaki, A., Raju, M., Dhariwal, M. & Kim, E.S. (2015) External validation of the HIT Expert Probability (HEP) score. Thrombosis and Haemostasis, 113, 633–640.
16. Kang, M., Alahmadi, M., Sawh, S., Kovacs, M.J. & Lazo-Langner, A. (2015) Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood, 125, 924–929.
17. Krauel, K., Hackbarth, C., Furll, B. & Greinacher, A. (2012) Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood, 119, 1248–1255.
18. Levine, R.L., Hursting, M.J. & McCollum, D. (2006) Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest, 129, 1167–1175.
19. Lewis, B.E., Wallis, D.E., Berkowitz, S.D., Matthai, W.H., Fareed, J., Walenga, J.M., Bartholomew, J., Sham, R., Lerner, R.G., Zeigler, Z.R., Rustagi, P.K., Jang, I.K., Rifkin, S.D., Moran, J., Hursting, M.J. & Kelton, J.G. (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation, 103, 1838–1843.
20. Lewis, B.E., Wallis, D.E., Leya, F., Hursting, M.J. & Kelton, J.G. (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Archives of Internal Medicine, 163, 1849–1856.
21. Linkins, L.A., Dans, A.L., Moores, L.K., Bona, R., Davidson, B.L., Schulman, S. & Crowther, M. (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141, e495S–e530S.
22. Linkins, L.A., Warkentin, T.E., Pai, M., Shivakumar, S., Manji, R.A., Wells, P.S. & Crowther, M.A. (2014) Design of the rivaroxaban for heparin-induced thrombocytopenia study. Journal of Thrombosis and Thrombolysis, 38, 485–492.
23. Linkins, L.A., Bates, S.M., Lee, A.Y., Heddle, N.M., Wang, G. & Warkentin, T.E. (2015) Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood, 126, 597–603.
24. Lo, G.K., Juhl, D., Warkentin, T.E., Sigouin, C.S., Eichler, P. & Greinacher, A. (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. Journal of Thrombosis and Haemostasis, 4, 759–765.
25. Martel, N., Lee, J. & Wells, P.S. (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood, 106, 2710–2715.
26. Mirdamadi, A. (2013) Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia. ARYA Atherosclerosis, 9, 112–114.
27. Nagler, M., Bachmann, L.M., Ten Cate, H. & Ten Cate-Hoek, A. (2016) Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 127, 546–557.
28. Nazi, I., Arnold, D.M., Warkentin, T.E., Smith, J.W., Staibano, P. & Kelton, J.G. (2015) Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 13, 1900–1907.
29. Ng, H.J., Than, H. & Teo, E.C. (2015) First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia. Thrombosis Research, 135, 205–207.
30. Pouplard, C., Gueret, P., Fouassier, M., Ternisien, C., Trossaert, M., Regina, S. & Gruel, Y. (2007) Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 5, 1373–1379.
31. Rollin, J., Pouplard, C., Sung, H.C., Leroux, D., Saada, A., Gouilleux-Gruart, V., Thibault, G. & Gruel, Y. (2015) Increased risk of thrombosis in FcgammaRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood, 125, 2397–2404.
32. Sartori, M., Favaretto, E., Cini, M., Legnani, C. & Cosmi, B. (2015) Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia. Journal of Thrombosis and Thrombolysis, 40, 392–394.
33. Schindewolf, M., Steindl, J., Beyer-Westendorf, J., Schellong, S., Dohmen, P.M., Brachmann, J., Madlener, K., Potzsch, B., Klamroth, R., Hankowitz, J., Banik, N., Eberle, S., Kropff, S., Muller, M.M. & Lindhoff-Last, E. (2014) Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)–findings from the GerHIT multi-centre registry study. Thrombosis Research, 134, 29–35.
34. Sharifi, M., Bay, C., Vajo, Z., Freeman, W., Sharifi, M. & Schwartz, F. (2015) New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thrombosis Research, 135, 607–609.
35. Swan, S.K. & Hursting, M.J. (2000) The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy, 20, 318–329.
36. Tardy-Poncet, B., Piot, M., Montmartin, A., Burdier, A., Chalayer, E. & Tardy, B. (2015) Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban. Thrombosis and Haemostasis, 114, 652–654.
37. Verma, A.K., Levine, M., Shalansky, S.J., Carter, C.J. & Kelton, J.G. (2003) Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy, 23, 745–753.
38. Walenga, J.M., Prechel, M., Jeske, W.P., Hoppensteadt, D., Maddineni, J., Iqbal, O., Messmore, H.L. & Bakhos, M. (2008) Rivaroxaban–an oral, direct Factor Xa inhibitor–has potential for the management of patients with heparin-induced thrombocytopenia. British Journal of Haematology, 143, 92–99.
39. Walenga, J.M., Prechel, M., Hoppensteadt, D., Escalante, V., Chaudhry, T., Jeske, W.P. & Bakhos, M. (2013) Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 19, 482–487.
40. Warkentin, T.E. (1998) Clinical presentation of heparin-induced thrombocytopenia. Seminars in Hematology, 35, 9–16; discussion 35-16.
41. Warkentin, T.E. (2006) Think of HIT. In: Hematology: The Education Program of the American Society of Hematology, pp. 408–414.
42. Warkentin, T.E. (2012) HITlights: a career perspective on heparin-induced thrombocytopenia. American Journal of Hematology, 87(Suppl. 1), S92–S99.
43. Warkentin, T.E. (2015a) Ischemic Limb Gangrene with Pulses. New England Journal of Medicine, 373, 642–655.
44. Warkentin, T.E. (2015b) Heparin-induced thrombocytopenia in critically ill patients. Seminars in Thrombosis and Hemostasis, 41, 49–60.
45. Warkentin, T.E. (2015c) Scoring systems for heparin-induced thrombocytopenia (HIT): whither now? Thrombosis and Haemostasis, 113, 437–438.
46. Warkentin, T.E. & Greinacher, A. (2003) Heparin-induced thrombocytopenia and cardiac surgery. Annals of Thoracic Surgery, 76, 2121–2131.
47. Warkentin, T.E. & Greinacher, A. (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 126, 311s–337s.
48. Warkentin, T.E. & Greinacher, A. (2009) Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opinion on Drug Safety, 8, 129–144.
49. Warkentin, T.E. & Heddle, N.M. (2003) Laboratory diagnosis of immune heparin-induced thrombocytopenia. Current Hematology Reports, 2, 148–157.
50. Warkentin, T.E. & Kelton, J.G. (2001) Temporal aspects of heparin-induced thrombocytopenia. New England Journal of Medicine, 344, 1286–1292.
51. Warkentin, T.E., Levine, M.N., Hirsh, J., Horsewood, P., Roberts, R.S., Gent, M. & Kelton, J.G. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New England Journal of Medicine, 332, 1330–1335.
52. Warkentin, T.E., Roberts, R.S., Hirsh, J. & Kelton, J.G. (2005) Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest, 127, 1857–1861.
53. Warkentin, T.E., Davidson, B.L., Buller, H.R., Gallus, A., Gent, M., Lensing, A.W., Piovella, F., Prins, M.H., Segers, A.E. & Kelton, J.G. (2011) Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest, 140, 366–373.
54. Warkentin, T.E., Chakraborty, A.K., Sheppard, J.A. & Griffin, D.K. (2012) The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thrombosis and Haemostasis, 108, 394–396.